Pernice, Helena F. http://orcid.org/0009-0001-8711-5526
Knorz, Adrian L. http://orcid.org/0000-0002-7924-0394
Wetzel, Paul J. http://orcid.org/0009-0001-9393-5512
Herrmann, Carolin http://orcid.org/0000-0003-2384-7303
Muratovic, Harisa
Rieber, Finn http://orcid.org/0009-0004-7833-2272
Asaad, Eleonora http://orcid.org/0009-0002-2677-3266
Fiß, Gunnar
Barzen, Gina http://orcid.org/0000-0002-1329-2159
Blüthner, Elisabeth http://orcid.org/0000-0002-7008-8795
Knebel, Fabian http://orcid.org/0000-0002-2095-6806
Spethmann, Sebastian http://orcid.org/0000-0003-0987-8007
Messroghli, Daniel
Heidecker, Bettina http://orcid.org/0000-0002-3811-7920
Brand, Anna
Wetz, Christoph http://orcid.org/0000-0002-7392-1375
Tschöpe, Carsten http://orcid.org/0000-0001-5243-8985
Hahn, Katrin http://orcid.org/0000-0002-6013-0072
Funding for this research was provided by:
Alnylam pharmaceutics
Deutsche Gesellschaft für Muskelkranke
Takeda Pharmaceuticals Inc.
Pfizer
Foundation Charité
Boehringer Ingelheim
AstraZeneca
Novartis
Charité - Universitätsmedizin Berlin
Article History
Received: 5 January 2024
Accepted: 17 April 2024
First Online: 2 May 2024
Competing interests
: Helena Pernice has received personal funding, travel support, and speaker fees by Alnylam Pharmaceuticals Inc. HP also received personal funding by Deutsche Gesellschaft für Muskelkranke (DGM) GmbH. Adrian Knorz, Gunnar Fiß, Harisa Muratovic, Paul Wetzel, Finn Rieber, Carolin Herrmann and Eleonora Asaad declare they have no conflict of interest. Katrin Hahn received financial reimbursement for consulting, advisory board activities, speaker fees and/or contributions to congresses and travel support to attend scientific meetings by Akcea Therapeuticals Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., Swedish Orphan Biovitrum Inc and ViiV Healthcare GmbH. KH further received research funding by the foundation Charité (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. Fabian Knebel received speaker honoraria from Alnylam Inc., Pfizer Inc., and research support from Alnylam Inc and Pfizer Inc. Christoph Wetz received a speaker honorarium from Company Novartis, Pfizer and Alnylam Pharmaceuticals; and received grants/research support from Novartis. Bettina Heidecker has received speaker fees and research funding from Pfizer Pharmaceuticals Inc., AstraZeneca, and Boehringer Ingelheim unrelated to this project. Fabian Knebel received speaker honoraria from Alnylam Inc., Pfizer Inc., and research support from Alnylam Inc and Pfizer Inc. Sebastian Spethmann received financial reimbursement for lectures from Pfizer Pharmaceuticals. Elisabeth Blüthner received consultation, lecture, advisory board honoraria and grant research support from Takeda Pharmaceuticals Inc. Anna Brand received a speaker honorarium from Pfizer. Daniel Messroghli has received honoraria for speaking at symposia from Pfizer, Alnylam and Akcea and research funding from Pfizer. Carsten Tschöpe has received speaker fees and/or contributions to congresses from Abbott, Abiomed, Astra Zeneca, Bayer, Novartis, Pfizer, and Servier; all outside the submitted work. Gina Barzen received personal funding by Alnylam Pharmaceuticals Inc.